Meeting
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
Authors
Jordan Kardos
Gilead Sciences, Inc., Foster City, CA
Jordan Kardos , Paola Correa , Sam Kim , Min Wang , Yang Pan , Li Li , Scott Donald Patterson , Shahed Iqbal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9034)
DOI
10.1200/JCO.2023.41.16_suppl.9034
Abstract #
9034
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2020 ASCO Virtual Scientific Program
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Jia Luo
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
First Author: Nicolas Guibert
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini